Medindia

X

ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009

Friday, February 5, 2010 Corporate News J E 4
Advertisement

SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- ResMed Inc. (NYSE: RMD) today announced record revenue and income results for the quarter ended December 31, 2009. Revenue for the December 2009 quarter was $275.1 million, a 23% increase (a 17% increase on a constant currency basis) over the quarter ended December 31, 2008. For the quarter ended December 31, 2009, income from operations was $57.9 million and net income was $46.0 million, an increase of 34% and 36%, respectively, compared to the quarter ended December 31, 2008. Diluted earnings per share for the quarter ended December 31, 2009 were $0.60, an increase of 36% compared to the quarter ended December 31, 2008.  

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100204/RESMEDLOGO)

SG&A costs were $84.1 million for the quarter ended December 31, 2009, an increase of $14.0 million or 20% (a 10% increase on a constant currency basis) over the quarter ended December 31, 2008. SG&A expenses were negatively impacted by the depreciation of the U.S. dollar against international currencies.  The increase in SG&A was primarily due to expenses necessary to support sales growth. SG&A costs were 31% of revenue in the quarter ended December 31, 2009, consistent with 31% in the quarter ended December 31, 2008.    

R&D expenses were $19.1 million for the quarter ended December 31, 2009, or approximately 7% of revenue. R&D expenses increased by 28% (a 1% increase on a constant currency basis) compared to the quarter ended December 31, 2008. R&D expenses were negatively impacted by the depreciation of the U.S. dollar against international currencies, particularly the Australian dollar.  

Amortization of acquired intangibles was $2.1 million ($1.4 million, net of tax) for the quarter ended December 31, 2009. Stock-based compensation costs incurred during the quarter ended December 31, 2009 of $7.3 million ($5.2 million, net of tax) consisted of expenses associated with stock options and restricted stock units granted to employees and our employee stock purchase plan.

During the quarter ended December 31, 2009, the company donated $1.0 million ($0.6 million, net of tax) to the ResMed Foundation. The Foundation's primary mission is to promote research, as well as public and physician awareness of the importance of sleep and respiratory health throughout the world.

For the six months ended December 31, 2009, revenue was $522.1 million, an increase of 18% over the six months ended December 31, 2008.  For the six months ended December 31, 2009, income from operations and net income were $110.6 million and $88.1 million, an increase of 38% and 42%, respectively, compared to the six months ended December 31, 2008.  Diluted earnings per share for the six months ended December 31, 2009 were $1.15 per diluted share, an increase of 44% compared to the six months ended December 31, 2008.

Inventory, at $182.9 million, increased by $25.4 million compared to June 30, 2009. Accounts receivable days sales outstanding, at 70 days, decreased by 4 days compared to June 30, 2009.

Kieran T. Gallahue, President and Chief Executive Officer, commented, "In the second quarter of fiscal 2010, we continued to show strong growth year over year.  Our favorable mix of product sales and market share gains led to a 20% increase in the Americas over the prior year's quarter, resulting in $148.0 million in revenue. Sales outside the Americas increased by 27% to $127.1 million over the prior year's quarter, or a 14% increase on a constant currency basis. Cash flow from operations for the December quarter was $11.6 million.  Operating cash flow was impacted by income tax payments totaling $61.7 million paid during the December quarter. Our robust revenue growth, recent product launches and exciting product pipeline continue to position us well for the future.

"As previously indicated, we are steadily introducing new products in what continues to be an exciting year for launching innovative treatment solutions for sleep-disordered breathing. This summer, we launched the ApneaLink™ Plus, our type 3 device for home sleep testing. More recently, we launched the Swift™ FX mask in Europe and the Mirage™ SoftGel mask in the Americas. These two new masks are receiving outstanding feedback from customers and patients as we continue their introduction ramp.  In addition, we are proud to announce the release of our newest generation of flow generators – the ResMed S9 series.  As is customary for ResMed, this initial introduction will be for the S9 AutoSet and S9 Elite products, expanding to other flow generators over time.  We expect the launch will begin in both Europe and the Americas during the third quarter of this fiscal year. The S9 should deliver innovative and meaningful new features to the ResMed product family while providing an exciting new look and feel.

"We are also continuing to drive market expansion.  We are taking steps to increase awareness of the health dangers of sleep-disordered breathing by sponsoring educational programs targeted at the primary care physician community. These efforts, driven both in concert with another industry participant and on our own, should further enlighten both doctors and patients about the relationship between sleep-disordered breathing/obstructive sleep apnea and co-morbidities such as cardiac disease, diabetes, hypertension and obesity.  They should also support our efforts to inform the community of the dangers of sleep apnea with regard to occupational health and safety, especially in the transport industry."  

About ResMed

ResMed is a leading developer, manufacturer and contributor of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

ResMed will host a conference call at 1:30 p.m. US Pacific Time today to discuss these quarterly results.  Individuals wishing to access the conference call may do so via ResMed's Website at www.resmed.com or by dialing (800) 659-2037 (domestic) or +1 (617) 614-2713 (international) and entering conference I.D. No. 11557939. Please allow extra time prior to the call to visit the Web site and download the streaming media player (Windows Media Player) required to listen to the Internet broadcast.  The online archive of the broadcast will be available approximately 90 minutes after the live call and will be available for two weeks.  A telephone replay of the conference call is available by dialing (888) 286-8010 (domestic) and +1 (617) 801-6888 (international) and entering conference I.D. No. 60219495.

Further information can be obtained by contacting Connie Bienfait at ResMed Inc., San Diego, at (858) 836-5971; Brett Sandercock at ResMed Limited, Sydney, on (+612) 8884-2090; or by visiting the Company's multilingual Web site at www.resmed.com.  

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission.  Those reports are available on the Company's Web site.

    
    
                             RESMED INC AND SUBSIDIARIES
                    Consolidated Statements of Income (Unaudited)
                     (In US$ thousands, except per share data)
    
                                   Three Months Ended        Six Months Ended
                                      December 31,             December 31,
                                   2009          2008        2009        2008
                                   ----          ----        ----        ----
    
    Net revenue                $275,134      $222,980    $522,126    $440,911
    Cost of sales               110,929        91,955     207,743     182,759
    -------------               -------        ------     -------     -------
    Gross profit                164,205       131,025     314,383     258,152
    ------------                -------       -------     -------     -------
    
    Operating expenses:
    Selling, general and
     administrative              84,094        70,086     160,850     141,424
    Research and development     19,059        14,915      36,973      32,208
    Amortization of acquired
     intangible assets            2,130         1,694       3,975       3,627
    Donation to Foundation        1,000         1,000       2,000       1,000
    ----------------------        -----         -----       -----       -----
    Total operating expenses    106,283        87,695     203,798     178,259
    ------------------------    -------        ------     -------     -------
    Income from operations       57,922        43,330     110,585      79,893
    ----------------------       ------        ------     -------      ------
    
    Other income (expenses),
     net:
    Interest income (expense),
     net                          3,166         2,666       5,290       5,898
    Other, net                    2,009           985       5,127         (83)
    ----------                    -----           ---       -----         ---
    Total other income
     (expenses), net              5,175         3,651      10,417       5,815
    ------------------            -----         -----      ------       -----
    
    Income before income taxes   63,097        46,981     121,002      85,708
    Income taxes                 17,114        13,128      32,917      23,829
    ------------                 ------        ------      ------      ------
    Net income                  $45,983       $33,853     $88,085     $61,879
    ----------                  -------       -------     -------     -------
    
    Basic earnings per share      $0.61         $0.45       $1.17       $0.82
    Diluted earnings per share    $0.60         $0.44       $1.15       $0.80
    
    Basic shares outstanding     75,123        75,742      75,272      75,678
    Diluted shares outstanding   77,034        77,358      76,874      77,269
    --------------------------   ------        ------      ------      ------ 
    
    
    
    
                       RESMED INC AND SUBSIDIARIES
                 Consolidated Balance Sheets (Unaudited)
            (In US$ thousands except share and per share data)
    
                                                 December 31,  June 30,
                                                     2009        2009
                                                     ----        ----
    Assets
    Current assets:
    Cash and cash equivalents                      $451,431    $415,650
    Accounts receivable, net                        208,947     212,096
    Inventories                                     182,870     157,431
    Deferred income taxes                            45,110      44,368
    Income taxes receivable                           6,762       2,067
    Prepaid expenses and other current assets        32,513      21,672
    -----------------------------------------        ------      ------
    Total current assets                            927,633     853,284
    --------------------                            -------     -------
    Property, plant and equipment, net              403,208     377,613
    Goodwill                                        225,094     213,169
    Other intangibles                                39,486      35,023
    Deferred Income taxes                            20,166      19,364
    Other assets                                      5,663       9,515
    ------------                                      -----       -----
    Total non-current assets                        693,617     654,684
    ------------------------                        -------     -------
    Total assets                                 $1,621,250  $1,507,968
    ------------                                 ----------  ----------
    Liabilities and Stockholders' Equity
    Current liabilities:
    Accounts payable                                $46,617     $48,293
    Accrued expenses                                 81,548      67,018
    Deferred revenue                                 31,954      28,881
    Income taxes payable                             27,005      56,972
    Deferred Income taxes                             2,970         391
    Current portion of long-term debt                50,525      67,545
    ---------------------------------                ------      ------
    Total current liabilities                       240,619     269,100
    -------------------------                       -------     -------
    Non Current Liabilities:
    Deferred income taxes                            10,363      11,137
    Deferred revenue                                 14,496      15,238
    Income taxes payable                              3,654       3,110
    Long-term debt                                   94,599      94,191
    --------------                                   ------      ------
    Total non-current liabilities                   123,112     123,676
    -----------------------------                   -------     -------
    Total liabilities                               363,731     392,776
    -----------------                               -------     -------
    Stockholders' Equity:
    Common Stock                                        301         301
    Additional paid-in capital                      580,099     522,982
    Retained earnings                               782,876     694,791
    Treasury stock                                 (274,488)   (208,659)
    Accumulated other comprehensive income          168,731     105,777
    --------------------------------------          -------     -------
    Total stockholders' equity                    1,257,519   1,115,192
    --------------------------                    ---------   ---------
    
    Total liabilities and stockholders' equity   $1,621,250  $1,507,968
    
    
    

SOURCE ResMed Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
BioMarin Announces 2010 Guidance
S
Update: Just in Time for Heart Health Month... TR...